ArticleNeuro-oncology advances

A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer.

Tiffany M Juarez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.